Further functional validation of BIRC5 may shed new light on mechanisms of afatinib-resistant in lung cancer, such as more details of mechanisms and signaling network involved in TKI resistance in LUAD as well as multi-center clinical trials of targeting BIRC5 in combination with TKIs or immunotherapy in NSCLC patients. This evidence concerns the gene BIRC5 and lung cancer.